{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(9)"],"submitter":["Hooper AT"],"pubmed_abstract":["Extra domain B splice variant of fibronectin (EDB+FN) is an extracellular matrix protein (ECM) deposited by tumor-associated fibroblasts, and is associated with tumor growth, angiogenesis, and invasion. We hypothesized that EDB+FN is a safe and abundant target for therapeutic intervention with an antibody-drug conjugate (ADC). We describe the generation, pharmacology, mechanism of action, and safety profile of an ADC specific for EDB+FN (EDB-ADC). EDB+FN is broadly expressed in the stroma of pancreatic, non-small cell lung (NSCLC), breast, ovarian, head and neck cancers, whereas restricted in normal tissues. In patient-derived xenograft (PDX), cell-line xenograft (CLX), and mouse syngeneic tumor models, EDB-ADC, conjugated to auristatin Aur0101 through site-specific technology, demonstrate"],"journal":["Molecular cancer therapeutics"],"pagination":["1462-1472"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9446899"],"repository":["biostudies-literature"],"pubmed_title":["Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade."],"pmcid":["PMC9446899"],"pubmed_authors":["Jain S","May C","Golas J","Rosfjord E","Hooper AT","Marquette K","Sapra P","Neri D","Loganzo F","Chang CB","Mathur D","Falahatpisheh H","O'Donnell C","Guffroy M","Kelleher K","Khandke K","Lucas J","Lam MH","Gerber HP","Leal M","Kan Z","Subramanyam C","Chen T","Muszynska E"],"additional_accession":[]},"is_claimable":false,"name":"Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.","description":"Extra domain B splice variant of fibronectin (EDB+FN) is an extracellular matrix protein (ECM) deposited by tumor-associated fibroblasts, and is associated with tumor growth, angiogenesis, and invasion. We hypothesized that EDB+FN is a safe and abundant target for therapeutic intervention with an antibody-drug conjugate (ADC). We describe the generation, pharmacology, mechanism of action, and safety profile of an ADC specific for EDB+FN (EDB-ADC). EDB+FN is broadly expressed in the stroma of pancreatic, non-small cell lung (NSCLC), breast, ovarian, head and neck cancers, whereas restricted in normal tissues. In patient-derived xenograft (PDX), cell-line xenograft (CLX), and mouse syngeneic tumor models, EDB-ADC, conjugated to auristatin Aur0101 through site-specific technology, demonstrate","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-22T04:28:04.671Z","creation":"2025-04-05T21:00:43.261Z"},"accession":"S-EPMC9446899","cross_references":{"pubmed":["35793468"],"doi":["10.1158/1535-7163.MCT-22-0099"]}}